Ligand Pharmaceuticals’ Captisol-enabled, propylene glycol-free drug melphalan has met all the endpoints in a Phase II trial treating patients with multiple myeloma.

Developed by Higuchi Biosciences Center, Captisol is a patent-protected, chemically altered cyclodextrin.

The Phase II study compared the safety, tolerability and pharmacokinetic profiles of an intravenous formulation of propylene glycol-free melphalan to the standard multiple myeloma treatment.

The Captisol-enabled drug will provide longer administration durations and slower infusion rates, enabling clinicians to safely achieve a higher dose intensity of pre-transplant chemotherapy.

The trial, conducted in partnership with The University of Kansas Cancer Center, is partially funded by the Kansas Bioscience Authority.

The company plans to begin the 60-patient pivotal trial to further evaluate the safety and efficacy of the drug candidate in 2012.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.